CD19嵌合抗原受体T细胞疗法后继发性髓系肿瘤的真实世界收集：ClonHema研究的首次报告 - Suppr

Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study.

作者信息

Farina Mirko, Bernardi Simona, Malagola Michele, Re Alessandro, Galli Eugenio, Riva Marcello, Cutini Ilaria, Leoni Alessandro, Martino Massimo, Ferrari Silvia, Battipaglia Giorgia, Novo Mattia, Musso Maurizio, Grillo Giovanni, Santarone Stella, Krampera Mauro, Aroldi Andrea, Polverelli Nicola, Arcaini Luca, Xhahysa Besjana, Avenoso Daniele, Tisi Maria Chiara, Chiusolo Patrizia, Russo Domenico

机构信息

Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

Centro di Ricerca Emato-oncologico AIL (CREA), ASST Spedali Civili di Brescia, Brescia, Italy.

出版信息

Bone Marrow Transplant. 2025 May;60(5):702-704. doi: 10.1038/s41409-025-02529-x. Epub 2025 Feb 15.

DOI:10.1038/s41409-025-02529-x

PMID:39955412

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12061764/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffdc/12061764/b02a1daa4cea/41409_2025_2529_Fig1_HTML.jpg

相似文献

Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study.CD19嵌合抗原受体T细胞疗法后继发性髓系肿瘤的真实世界收集：ClonHema研究的首次报告

Bone Marrow Transplant. 2025 May;60(5):702-704. doi: 10.1038/s41409-025-02529-x. Epub 2025 Feb 15.

Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.嵌合抗原受体 T 细胞（CAR T）治疗难治/复发 B 细胞淋巴瘤后发生的继发性髓系肿瘤：病例系列及文献复习。

Front Immunol. 2023 Jan 13;13:1063986. doi: 10.3389/fimmu.2022.1063986. eCollection 2022.

Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma.难治性/复发性淋巴瘤患者接受CD19嵌合抗原受体T细胞（CAR T）治疗后发生的继发性骨髓增生异常综合征

Clin Lab. 2025 Feb 1;71(2). doi: 10.7754/Clin.Lab.2024.240910.

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.在复发或难治性弥漫性大B细胞淋巴瘤的CD19导向嵌合抗原受体T细胞疗法之前使用塔法昔单抗的真实世界应用。

Biomark Res. 2025 Jan 23;13(1):18. doi: 10.1186/s40364-024-00706-6.

Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.弥漫性大 B 细胞淋巴瘤患者接受 CD19 导向嵌合抗原受体 T 细胞治疗后的真实世界治疗模式。

Adv Ther. 2022 Jun;39(6):2630-2640. doi: 10.1007/s12325-022-02087-4. Epub 2022 Apr 9.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.获得CD19阴性髓系表型可使MLL重排的B细胞急性淋巴细胞白血病从CD19嵌合抗原受体T细胞疗法中实现免疫逃逸。

Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.真实世界中 CD19 特异性嵌合抗原受体 T 细胞治疗后严重神经毒性的 T 细胞动力学和迁移的分子监测。

Haematologica. 2023 Feb 1;108(2):444-456. doi: 10.3324/haematol.2022.281110.

Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.CD19 定向疗法在接受 CD19 定向嵌合抗原受体 T 细胞治疗后复发的复发或难治性大 B 细胞淋巴瘤患者中的疗效。

Bone Marrow Transplant. 2024 Feb;59(2):211-216. doi: 10.1038/s41409-023-02148-4. Epub 2023 Nov 16.

Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression.用于复发/难治性急性髓系白血病（AML）且伴有异常CD19抗原表达的即时检测CD19嵌合抗原受体（CAR）T细胞

Curr Res Transl Med. 2024 Dec;72(4):103471. doi: 10.1016/j.retram.2024.103471. Epub 2024 Sep 15.

High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review.复发弥漫性大B细胞淋巴瘤患者接受CAR T细胞治疗后发生的高危骨髓增生异常综合征：1例病例报告及文献综述

Front Oncol. 2023 Jan 20;13:1036455. doi: 10.3389/fonc.2023.1036455. eCollection 2023.

引用本文的文献

Mutation as a Distinct Feature of Myeloid Neoplasms in B-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis.B细胞非霍奇金淋巴瘤患者髓系肿瘤的独特特征——突变：一项回顾性分析

Cancers (Basel). 2025 Mar 31;17(7):1185. doi: 10.3390/cancers17071185.

本文引用的文献

Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.淋巴瘤中CD-19导向的嵌合抗原受体T细胞疗法后的继发性原发性恶性肿瘤：来自意大利CART-SIE研究的报告。

Br J Haematol. 2024 Oct;205(4):1356-1360. doi: 10.1111/bjh.19590. Epub 2024 Jun 15.

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.CAR T 细胞治疗后第二肿瘤和 T 细胞淋巴瘤的风险。

N Engl J Med. 2024 Jun 13;390(22):2047-2060. doi: 10.1056/NEJMoa2401361.

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.商业 CAR T 细胞治疗后的第二原发性恶性肿瘤：FDA 不良事件报告系统分析。

Blood. 2024 May 16;143(20):2099-2105. doi: 10.1182/blood.2024024166.

FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-t Cells.CD19嵌合抗原受体T细胞治疗后出现的FLT3突变急性髓系白血病

Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024029. doi: 10.4084/MJHID.2024.029. eCollection 2024.

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.商业 CAR T 细胞治疗后 T 细胞淋巴瘤和继发原发性恶性肿瘤风险。

Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24.

Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study.丹麦淋巴瘤患者接受大剂量化疗和自体造血干细胞移植后的第二原发性恶性肿瘤：一项基于人群的回顾性队列研究。

Lancet Haematol. 2023 Oct;10(10):e838-e848. doi: 10.1016/S2352-3026(23)00212-0. Epub 2023 Sep 6.

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.免疫效应细胞相关血液学毒性：EHA/EBMT 共识分级和最佳实践建议。

Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.

Front Oncol. 2023 Jan 20;13:1036455. doi: 10.3389/fonc.2023.1036455. eCollection 2023.

Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors.非霍奇金淋巴瘤中的第二原发性恶性肿瘤：流行病学和危险因素。

Ann Hematol. 2023 Feb;102(2):249-259. doi: 10.1007/s00277-023-05095-8. Epub 2023 Jan 9.

Diagnosis and treatment of therapy-related acute myeloid leukemia.治疗相关性急性髓系白血病的诊断和治疗。

Crit Rev Oncol Hematol. 2022 Mar;171:103607. doi: 10.1016/j.critrevonc.2022.103607. Epub 2022 Jan 31.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献